GENERIC DRUG: PRESCRIBER’S PERSPECTIVE
Objective: Knowledge of doctors and their understanding of generic drugs could facilitate in recognizing potential barriers to larger generic medicine prescriptions. Hence, the primary objective of this study was focused to explore knowledge, attitude, and practice (KAP) of doctors toward generic medicines.
Methods: It is a cross-sectional questionnaire-based study. The study participants are the doctors working in the hospital during the study period (2016–2017). The questionnaire designed for this study comprised of thirty-five questions related to the knowledge, attitude, and practice (KAP) of generic medicine and about demographic details of the participants.
Results: A total of 86 questionnaires were distributed among the health care professionals and the response rate is 37%. The majority of doctors who participated in this survey perceived that generic medicine is effective, safe and need to have the same active component, dose and bioequivalent as the brand name medicines. Most of the doctors (72%) were of the view that generic drugs were manufactured in poor quality than branded medicines. More than three-quarters of doctors (78%) prescribed generic drugs.
Conclusion: Majority of the participants had an honest angle about the efficaciousness and safety of generic and though they sometimes prescribe generic medicine, however a high range of doctors (72%) were of the opinion that generic was of poorer quality than brand medicine. To have a better understanding of the generic drug, the doctor must be well informed about the generics during their academic career resulting in savings to healthcare budgets.
2. Kumar AS, Chen LC, Choudhury M, Ganju S, Mahajan V, Sinha A, et al. Financing health care for all: challenges and opportunities. Lancet 2011;377:668-79.
3. Haas JS, Phillips KA, Gerstenberger EP, Seger AC. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997–2000. Ann Intern Med 2005;142:891-7.
4. Shaik, Muragundi. Evaluation of price disparity among generic medicines in India. Asian J Pharm Clin Res 2018;11:466–8.
5. Hansen Nasif, Henny Lucida, Yanwirasti Yanwirasti, Yufri Aldi, Yori Yuliandra. Pharmacodynamics effect of methylprednisolone tablets onthe serum concentration of annexin a1: in vivo comparative study between generic and innovator drug. Asian J Pharm Clin Res 2019;12:414-7.
6. Chong CP, Bahari B. Generic subtitution in community pharmacies of penang area. Malays J Pharm Sci 2005;3:74.
7. Alrasheedy AA, Hassali MA, Aljadhey H, Ibrahim MI, Al-Tamimi SK. Is there a need for a formulary of clinically interchangeable medicines to guide generic substitution in Saudi Arabia? J Young Pharm 2013;5:73-5.
8. Singal GL, Nanda A, Kotwani A. A comparative evaluation of price and quality of some branded versus branded–generic medicines of the same manufacturer in India. Indian J Pharmacol 2011;43:131.
9. Shrank WH, Liberman JN, Fischer MA, Girdish C, Brennan TA, Choudhry NK. Physician perceptions about generic drugs. Ann Pharmacother 2011;45:31-8.
10. Kumar R, Hassali MA, Saleem F, Alrasheedy AA, Kaur N, Wong ZY, et al. Knowledge and perceptions of physicians from private medical centres towards generic medicines: a nationwide survey from Malaysia. J Pharm Policy Pract 2015;8:11.
11. Jamshed SQ, Ibrahim MI, Hassali MA, Masood I, Low BY, Shafie AA. Perception and attitude of general practitioners regarding generic medicines in Karachi, Pakistan: a questionnaire based study. South Med Rev 2012;5:22.
12. Chua GN, Hassali MA, Shafie AA, Awaisu A. A survey exploring knowledge and perceptions of general practitioners towards the use of generic medicines in the northern state of Malaysia. Health Policy 2010;95:229-35.
13. Hassle MA, Shafie AA, Awaisu A, Ibrahim MI, Ping CC, Jamshed S. Physicians' views on generic medicines: a narrative review. J Generic Med 2010;7:30-9.
14. Dunne SS, Shannon B, Cullen W, Dunne CP. Beliefs, perceptions and behaviours of GPs towards generic medicines. Fam Pract 2014;31:467-74.
15. Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH, Patel DT, et al. Comparing generic and innovator drugs: a review of 12 y of bioequivalence data from the United States food and drug administration. Ann Pharmacother 2009;43:1583-97.
16. Amit G, Rosen A, Wagshal AB, Bonneh DY, Liss T, Grosbard A, et al. Efficacy of substituting innovator propafenone for its generic formulation in patients with atrial fibrillation. Am J Cardiol 2004;93:1558-60.
17. Araszkiewicz AA, Szabert K, Godman B, Wladysiuk M, Barbui C, Haycox A. Generic olanzapine: health authority opportunity or nightmare?. Expert Rev Pharm Out 2008;8:549-55.
18. Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA J Am Med Assoc 2008;300:2514-26.
19. Kesselheim AS, Stedman MR, Bubrick EJ, Gagne JJ, Misono AS, Lee JL, et al. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs. Drugs 2010;70:605-21.
20. Lopes GD. Cost comparison and economic implications of commonly used originator and generic chemotherapy drugs in India. Ann Oncol 2013;24:13-6.
21. Jayaraman K. Troubles beset 'Jan Aushadhi' plan to broaden access to generics. 2010;16:350.
22. Prasad. Knowledge, attitude, and practice of generic drugs among doctors in a tertiary care hospital. Innovare J Med Science 2019;7:1-3.
23. Tsiantou V, Zavras D, Kousoulakou H, Geitona M, Kyriopoulos J. Generic medicines: greek physicians’ perceptions and prescribing practices. J Clin Pharm Ther 2009;34:547-54.
24. DeJong C, Aguilar T, Tseng CW, Lin GA, Boscardin WJ, Dudley RA. Pharmaceutical industry-sponsored meals and physician prescribing patterns for medicare beneficiaries. JAMA Intern Med 2016;176:1114-22.
25. Mahajan R, Singh NR, Singh J, Dixit A, Jain A, Gupta A. Current scenario of attitude and knowledge of physicians about rational prescription: a novel cross-sectional study. J Pharm Bioallied Sci 2010;2:132-6.
26. Dylst P, Vulto A, Simoens S. Where a cheap medicine is not the same as a generic medicine: the Belgian case. J Pharm Health Serv Res 2011;2:185-9.
27. Suh DC. Trends of generic substitution in community pharmacies. Pharm World Sci 1999;21:260-5.
28. Steinman MA, Chren MM, Landefeld CS. What’s in a name? Use of brand versus generic drug names in United States outpatient practice. J Gen Intern Med 2007;22:645-8.
29. Kwo EC, Kamat P, Steinman MA. Physician use of brand versus generic drug names in 1993–1994 and 2003-2004. Ann Pharmacother 2009;43:459-68.
30. Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, et al. Policies to enhance prescribing efficiency in Europe: findings and future implications. Front Pharmacol 2011;1:141.
31. Godman B, Wettermark B, Bishop I, Burkhardt T, Fürst J, Garuoliene K, et al. European payer initiatives to reduce prescribing costs through use of generics. GaBi J 2012;1:22-7.
32. Von?ina L, Strizrep T, Godman B, Bennie M, Bishop I, Campbell S, et al. Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future. Expert Rev Pharm Out 2011;11:469-79.
33. Fabiano V, Mameli C, Cattaneo D, DelleFave A, Preziosa A, Mele G, et al. Perceptions and patterns of use of generic drugs among Italian family pediatricians: first-round results of a web survey. Health Policy 2012;104:247-52.
34. Pandiamunian, Kartik J Salwe, Somasundaram G, Bhanu Prakash Kolasani. A study on the prescribing pattern of antimicrobial agents in the neonatal intensive care unit of a tertiary care teaching hospital in puducherry, South India. Asian J Pharm Clin Res 2016;6:217-20.
This work is licensed under a Creative Commons Attribution 4.0 International License.